| 86.07 -0.85 (-0.98%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 105.71 | 1-year : | 112.46 |
| Resists | First : | 90.5 | Second : | 96.29 |
| Pivot price | 85.9  |
|||
| Supports | First : | 81.15 | Second : | 67.52 |
| MAs | MA(5) : | 85.09 |
MA(20) : | 87.78 |
| MA(100) : | 84.55 |
MA(250) : | 82.52 |
|
| MACD | MACD : | -1.1 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 42.5 |
D(3) : | 33.4 |
| RSI | RSI(14): 47.2 |
|||
| 52-week | High : | 96.29 | Low : | 72.3 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EW ] has closed below upper band by 48.3%. Bollinger Bands are 26.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 87.15 - 87.59 | 87.59 - 87.87 |
| Low: | 84.19 - 84.77 | 84.77 - 85.15 |
| Close: | 85.23 - 86.11 | 86.11 - 86.68 |
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Fri, 31 Jul 2026
Edwards Lifesciences (EW) Insider Wayne Markowitz Sells 146 Shar - GuruFocus
Thu, 30 Jul 2026
Edwards Lifesciences CVP Markowitz sells $12,587 of company stock - Investing.com
Thu, 30 Jul 2026
Edwards Lifesciences (NYSE: EW) executive files to sell 50K shares - Stock Titan
Thu, 30 Jul 2026
Edwards Lifesciences (EW) holder Wayne Markowitz reports recent stock sales - Stock Titan
Thu, 30 Jul 2026
Is the Options Market Predicting a Spike in Edwards Lifesciences Stock? - Yahoo Finance
Thu, 30 Jul 2026
Edwards Lifesciences Corporation $EW Stake Raised by Quantinno Capital Management LP - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 576 (M) |
| Shares Float | 574 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 94.3 (%) |
| Shares Short | 11,350 (K) |
| Shares Short P.Month | 11,800 (K) |
| EPS | 1.67 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 17.89 |
| Profit Margin | 15.4 % |
| Operating Margin | 29.8 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 13.6 % |
| Gross Profit (p.s.) | 8.8 |
| Sales Per Share | 11.3 |
| EBITDA (p.s.) | 3.47 |
| Qtrly Earnings Growth | -25.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 51.23 |
| PEG Ratio | 2 |
| Price to Book value | 4.8 |
| Price to Sales | 7.61 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|